Pathos AI Completes Acquisition of Rain Oncology
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (www.pathos.com), today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to...
Read More
Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor
Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051 Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug...
Read More
Re-engineering Drug Development for Precision Medicine
There’s no worse feeling than watching a loved one fight bravely through a cancer diagnosis and battle through treatments while hoping for a miracle or a little more time. Suddenly, your doctor tells you that there's nothing more they can...